Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
AGIO

AGIO - Agios Pharmaceuticals Inc Stock Price, Fair Value and News

$28.31-0.36 (-1.26%)
Market Closed

70/100

AGIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

70/100

AGIO

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$36.79

Target 3M

$30.42

Target 6M

$32.39

AGIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AGIO Price Action

Last 7 days

4.2%

Last 30 days

4.2%

Last 90 days

-34.4%

Trailing 12 Months

-15.6%

AGIO RSI Chart

AGIO Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

AGIO Valuation

Market Cap

1.7B

Price/Earnings (Trailing)

-4.11

Price/Sales (Trailing)

36.86

EV/EBITDA

2.24

Price/Free Cashflow

-3.99

AGIO Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$36.79

Target 3M

$30.42

Target 6M

$32.39

AGIO Fundamentals

AGIO Revenue

Revenue (TTM)

44.8M

Rev. Growth (Yr)

43.69%

Rev. Growth (Qtr)

3.41%

AGIO Earnings

Earnings (TTM)

-401.3M

Earnings Growth (Yr)

-110.91%

Earnings Growth (Qtr)

7.67%

AGIO Profitability

EBT Margin

1554.47%

Return on Equity

-31.24%

Return on Assets

-28.96%

Free Cashflow Yield

-25.08%

AGIO Investor Care

Shares Dilution (1Y)

2.25%

Diluted EPS (TTM)

-6.85

AGIO Alerts

  • 1 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202537.0M40.9M44.8M0
202429.4M31.3M32.9M36.5M
202317.2M22.1M26.0M26.8M
202285.0M45.6M6.3M12.3M
20210163.8M124.4M0
2020174.8M184.3M193.7M203.2M
2019115.9M101.7M112.5M117.9M
201841.3M70.3M74.2M94.4M
201749.1M53.5M55.9M43.0M
201656.2M50.0M53.5M69.9M
201591.1M96.0M67.5M59.1M
201427.7M29.8M57.5M65.4M
201325.1M25.1M25.1M25.5M
201222.7M23.5M24.3M25.1M
201100021.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Agios Pharmaceuticals Inc

AGIO
Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism. The company develops PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias; and AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEagios.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES389

Agios Pharmaceuticals Inc Frequently Asked Questions

AGIO is the stock ticker symbol of Agios Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Agios Pharmaceuticals Inc is 1.65 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check AGIO's fair value in chart for subscribers.

The fair value guage provides a quick view whether AGIO is over valued or under valued. Whether Agios Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Agios Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGIO.

As of Wed Jan 28 2026, AGIO's PE ratio (Price to Earnings) is -4.11 and Price to Sales (PS) ratio is 36.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGIO PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Agios Pharmaceuticals Inc has provided -0.039 (multiply by 100 for percentage) rate of return.